CompMedChem
康迈迪森科技
CompMedChem is an AI drug discovery company focused on lead compound screening, founded by Wan Xiaobo, who serves as its co-founder and CEO . It was part of FreeS Fund's portfolio in the computational drug discovery space, alongside better-known peers such as XtalPi, Chemical.AI, and METiS Pharmaceuticals . FreeS Fund partner Ma Rui listed CompMedChem among his representative projects in the materials and biotech track, which centers on computation-driven and synthetic-biology approaches . In FreeS Fund's 2026 retrospective on its systematic pharmaceutical-chain investments, CompMedChem was described as the bet positioned "downstream from molecular design," complementing upstream bets such as XtalPi (crystal form) and METiS (dosage form) . elsewhere's corpus does not contain further detail on its financing history or current pipeline.
AI-generated — may contain errors, please verify.
Coverage
Are Returnee Entrepreneurs Losing Their Edge? | 2021 FreeS Fund China-US Venture Forum Transcript
Launch a Startup or Take the "Soft Landing" Through Employment?
What's It Like Doing Venture Capital in China? | 2021 FreeS Fund China-US VC Forum Transcript
How do you know if you're cut out for investing? What challenges will you face along the way?
FreeS Report 21: In Search of China's Classics and Fashion — A Study on Guochao Consumption | FreeS Research Institute
Every category will see the rise of influential guochao brands.
FreeS Fund China-US Venture Capital Forum Registration Now Open | Seizing New Opportunities in China's Era
Whether you're looking for a job or starting a company, feel free to come chat with us at FreeS Fund.
